Table 6.
Comparison of demographic, clinical, and laboratory variables among the previously and newly diagnosed type-2 diabetes patients.
| Previously diagnosed diabetes mellitus (n = 587) | Newly diagnosed diabetes mellitus (n = 39) | ||
|---|---|---|---|
| Age | 65.70 (±60.13) | 60.13 (±15.02) | 0.016 |
| BMI | 29.91 (±33.05) | 33.05 (±9.17) | 0.021 |
| Mortality | 237 (40.37%) | 7 (17.95%) | 0.005 |
| Mechanical ventilation | 240 (40.89%) | 10 (25.64%) | 0.06 |
|
| |||
| Gender | |||
| Female | 243 (41.40%) | 15 (38.46%) | |
| Male | 344 (58.60%) | 24 (61.54%) | |
|
| |||
| Ethnicity | 0.013 | ||
| Black | 174 (29.64%) | 7 (17.95%) | |
| Caucasian | 11 (01.87%) | 0 (00.00%) | |
| Hispanic | 350 (59.63%) | 24 (61.54%) | |
| Others | 52 (08.86%) | 8 (20.51%) | |
|
| |||
| Clinical presentation | |||
| Fever | 342 (58.26%) | 26 (66.67%) | 0.303 |
| Cough | 350 (59.63%) | 29 (74.36%) | 0.068 |
| Shortness of breath | 377 (64.22%) | 31 (79.49%) | 0.053 |
| Myalgia | 155 (26.41%) | 11 (28.21%) | 0.806 |
| Headache | 40 (06.81%) | 6 (15.38%) | 0.047 |
| Nausea/vomiting | 82 (13.97%) | 5 (12.82%) | 0.841 |
| Abdominal discomfort | 198 (33.73%) | 7 (17.95%) | 0.042 |
| Diarrhea | 78 (13.29%) | 7 (17.95%) | 0.411 |
|
| |||
| Comorbid medical conditions | |||
| HIV/AIDS | 39 (06.67%) | 1 (02.56%) | 0.312 |
| Hypertension | 460 (78.63%) | 22 (56.41%) | 0.001 |
| Congestive heart failure | 72 (12.31%) | 3 (07.69%) | 0.392 |
| Coronary artery disease | 92 (15.73%) | 5 (12.82%) | 0.628 |
| Chronic kidney disease | 72 (12.33%) | 2 (05.13%) | 0.179 |
|
| |||
| SARS-CoV-2 management | |||
| Hydroxychloroquine | 464 (79.05%) | 34 (87.18%) | 0.223 |
| Antiviral agents | 45 (7.67%) | 7 (17.95%) | 0.024 |
| Antibiotics | 561 (95.57%) | 39 (100.00%) | 0.18 |
| Tamiflu | 58 (9.88%) | 3 (7.69%) | 0.656 |
| Remdesivir | 5 (0.85%) | 2 (5.13%) | 0.014 |
| Anticonvalescent plasma | 17 (02.90%) | 3 (07.69%) | 0.09 |
| Steroids | 214 (36.46%) | 23 (58.97%) | 0.005 |
| Therapeutic anticoagulation | 365 (62.18%) | 29 (74.36%) | 0.128 |
| Tocilizumab | 57 (09.71%) | 8 (20.51%) | 0.032 |
|
| |||
| Laboratory parameters | |||
| Serum creatinine | 2.25 (±1.46) | 1.46 (±1.51) | 0.063 |
| White blood cell count | 8.93 (±8.94) | 8.94 (±3.76) | 0.993 |
| Absolute neutrophil count | 7.13 (±7.41) | 7.41 (±3.60) | 0.691 |
| Absolute lymphocyte count | 1.19 (±0.90) | 0.90 (±0.45) | 0.737 |
| ANCALC ratio | 10.19 (±10.29) | 10.29 (±8.93) | 0.959 |
| D-dimer | 414.19 (±435.77) | 435.77 (±252.31) | 0.582 |
| Serum lactate dehydrogenase | 446.99 (±456.26) | 456.26 (±189.55) | 0.793 |
| C-reactive protein | 141.87 (±177.39) | 177.39 (±134.83) | 0.059 |